FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to a method for the treatment of cancer expressing fibroblast growth factor Receptor 2 (FGFR2) IIIb.
EFFECT: proposed method, including the introduction of an antibody to the fibroblast growth factor Receptor 2 (FGFR2) IIIb and an inhibitor of the programmed cell death protein 1 (PD-1) or an inhibitor of Ligand 1 of the programmed cell death protein (PD-L1), can be used to change the tumor microenvironment and enhance tumor-destroying immune responses in effective therapy of FGFR2-IIIb-expressing tumors.
41 cl, 16 dwg, 3 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
| ANTIBODIES TO PD-1 AND THEIR APPLICATION | 2017 |
|
RU2761640C2 |
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
| METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES | 2019 |
|
RU2825835C2 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| MANAGEMENT, NAVIGATION AND CONTROL PROTEINS AND METHOD OF THEIR OBTAINING AND USE | 2019 |
|
RU2811457C2 |
| ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE | 2019 |
|
RU2795457C2 |
| ANTI-PD-1 ANTIBODY | 2015 |
|
RU2722212C2 |
| ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
| COMBINATIONS OF ANTIBODIES FOR TREATING CANCER IN SPECIFIC PATIENTS | 2020 |
|
RU2816531C2 |
